{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:35:50Z","timestamp":1778056550939,"version":"3.51.4"},"reference-count":43,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","ajconline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.amjcard.2017.07.072","type":"journal-article","created":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T18:31:57Z","timestamp":1501612317000},"page":"1689-1695","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Meta-Analysis of Effectiveness and Safety of Oral Anticoagulants in Atrial Fibrillation With Focus on Apixaban"],"prefix":"10.1016","volume":"120","author":[{"given":"Ying","family":"Bai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu-Bo","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Sheng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2017.07.072_bib0010","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0140-6736(16)31257-0","article-title":"Stroke prevention in atrial fibrillation","volume":"388","author":"Freedman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0015","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0020","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1161\/STROKEAHA.115.009947","article-title":"Non-vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation: meta-analysis","volume":"46","author":"Wang","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0025","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0030","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0035","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0040","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0045","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0050","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1177\/1060028014563950","article-title":"Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation","volume":"49","author":"Armbruster","year":"2015","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0055","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/pace.12618","article-title":"Novel oral anticoagulants for DC cardioversion procedures: utilization and clinical outcomes compared with warfarin","volume":"38","author":"Coleman","year":"2015","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0060","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.hrthm.2015.02.028","article-title":"Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: results from a multicenter study","volume":"12","author":"Di Biase","year":"2015","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0065","first-page":"A5186","article-title":"Safety of novel oral anticoagulants in catheter ablation of atrial fibrillation","volume":"63","author":"Hansen","year":"2016","journal-title":"Dan Med J"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0070","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.amjcard.2014.10.005","article-title":"Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon","volume":"115","author":"Kaess","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0075","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/1755-5922.12178","article-title":"The total incidence of complications and the impact of an anticoagulation regime on adverse events after cryoballoon ablation of atrial fibrillation: a single-center study of 409 patients","volume":"34","author":"Koektuerk","year":"2016","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0080","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/jce.12928","article-title":"Apixaban versus warfarin for the prevention of periprocedural cerebral thromboembolism in atrial fibrillation ablation: multicenter prospective randomized study","volume":"27","author":"Kuwahara","year":"2016","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0085","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/pace.12553","article-title":"Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation","volume":"38","author":"Nagao","year":"2015","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0090","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1253\/circj.CJ-15-1368","article-title":"Silent cerebral ischemic lesions after catheter ablation of atrial fibrillation in patients on 5 types of periprocedural oral anticoagulation- predictors of diffusion-weighted imaging-positive lesions and follow-up magnetic resonance imaging","volume":"80","author":"Nakamura","year":"2016","journal-title":"Circ J"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0095","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jjcc.2016.04.009","article-title":"Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation","volume":"69","author":"Okishige","year":"2017","journal-title":"J Cardiol"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0100","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/jce.12856","article-title":"Apixaban, rivaroxaban, and dabigatran in patients undergoing atrial fibrillation ablation","volume":"27","author":"Rillig","year":"2016","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0105","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jjcc.2016.03.014","article-title":"Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation","volume":"69","author":"Yoshimura","year":"2017","journal-title":"J Cardiol"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0110","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0115","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1253\/circj.CJ-10-1183","article-title":"Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. The ARISTOTLE-J study","volume":"75","author":"Ogawa","year":"2011","journal-title":"Circ J"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0120","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1160\/TH16-05-0403","article-title":"Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis","volume":"116","author":"Lip","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0125","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1080\/03007995.2016.1237937","article-title":"Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study","volume":"32","author":"Coleman","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0130","doi-asserted-by":"crossref","first-page":"i3189","DOI":"10.1136\/bmj.i3189","article-title":"Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study","volume":"353","author":"Larsen","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0135","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/ehjcvp\/pvw031","article-title":"A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants","volume":"3","author":"Halvorsen","year":"2017","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0140","first-page":"907","article-title":"Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study","volume":"38","author":"Staerk","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0145","doi-asserted-by":"crossref","first-page":"e003725","DOI":"10.1161\/JAHA.116.003725","article-title":"Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation","volume":"5","author":"Yao","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0150","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.chest.2016.07.013","article-title":"Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation","volume":"150","author":"Noseworthy","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0155","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1185\/03007995.2016.1142432","article-title":"The safety and persistence of non-vitamin-K-antagonist oral anticoagulants in atrial fibrillation patients treated in a well structured atrial fibrillation clinic","volume":"32","author":"Al-Khalili","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0160","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s11239-016-1410-z","article-title":"Direct oral anticoagulant use and the incidence of bleeding in the very elderly with atrial fibrillation","volume":"42","author":"Khan","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0165","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/ijcp.12712","article-title":"Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic","volume":"69","author":"Lee","year":"2015","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0170","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1177\/1076029615619485","article-title":"Direct oral anticoagulants for very elderly people with atrial fibrillation: efficacy and safe enough?","volume":"23","author":"Pasca","year":"2017","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0175","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1185\/03007995.2015.1131676","article-title":"An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants","volume":"32","author":"Deitelzweig","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0180","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11739-017-1624-x","article-title":"Real-world evidence with apixaban for stroke prevention in patients with nonvalvular atrial fibrillation in Germany: a retrospective study (REASSESS)","volume":"12","author":"Coleman","year":"2017","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0185","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s00392-017-1098-x","article-title":"Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study","volume":"106","author":"Hohnloser","year":"2017","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0190","doi-asserted-by":"crossref","first-page":"e004517","DOI":"10.1161\/JAHA.116.004517","article-title":"Major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation: contemporary findings in real-life Danish patients","volume":"6","author":"Lamberts","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0195","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1160\/TH17-01-0068","article-title":"Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in \u201creal-world\u201d clinical practice. A propensity-matched analysis of 76,940 patients","volume":"117","author":"Li","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0200","doi-asserted-by":"crossref","first-page":"j510","DOI":"10.1136\/bmj.j510","article-title":"Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study","volume":"356","author":"Nielsen","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0205","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1161\/CIRCOUTCOMES.112.965988","article-title":"Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation","volume":"5","author":"Schneeweiss","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0210","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10840-016-0141-6","article-title":"Apixaban for periprocedural anticoagulation during catheter ablation of atrial fibrillation: a systematic review and meta-analysis of 1691 patients","volume":"46","author":"Blandino","year":"2016","journal-title":"J Interv Card Electrophysiol"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0215","first-page":"1368","article-title":"Safety and efficacy of uninterrupted periprocedural apixaban in patients undergoing atrial fibrillation catheter ablation: a metaanalysis of 1,057 patients","volume":"8","author":"Garg","year":"2016","journal-title":"J Atr Fibrillation"},{"key":"10.1016\/j.amjcard.2017.07.072_bib0220","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/europace\/euw368","article-title":"Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation","volume":"19","author":"Di Biase","year":"2017","journal-title":"Europace"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914917312456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914917312456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T23:35:54Z","timestamp":1655422554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914917312456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0002914917312456"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2017.07.072","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meta-Analysis of Effectiveness and Safety of Oral Anticoagulants in Atrial Fibrillation With Focus on Apixaban","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2017.07.072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}